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Abstract
A major challenge for further development of drug screening procedures, cell replacement therapies and developmental
studies is the identification of expandable human stem cells able to generate the cell types needed. We have previously
reported the generation of an immortalized polyclonal neural stem cell (NSC) line derived from the human fetal ventral
mesencephalon (hVM1). This line has been biochemically, genetically, immunocytochemically and electrophysiologically
characterized to document its usefulness as a model system for the generation of A9 dopaminergic neurons (DAn). Long-
term in vivo transplantation studies in parkinsonian rats showed that the grafts do not mature evenly. We reasoned that
diverse clones in the hVM1 line might have different abilities to differentiate. In the present study, we have analyzed 9 hVM1
clones selected on the basis of their TH generation potential and, based on the number of v-myc copies, v-myc down-
regulation after in vitro differentiation, in vivo cell cycle exit, TH+ neuron generation and expression of a neuronal mature
marker (hNSE), we selected two clones for further in vivo PD cell replacement studies. The conclusion is that homogeneity
and clonality of characterized NSCs allow transplantation of cells with controlled properties, which should help in the design
of long-term in vivo experiments.
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Introduction
The development of neural transplantation as a treatment for
Parkinson’s disease moved to the clinics after obtaining convincing
results in animal models of Parkinson’s Disease (PD). Clinical
research on neuron replacement using human fresh ventral
mesencephalon tissue (hfVM) provided proof of principle of the
therapeutic efficacy of dopaminergic transplants on a long-term
basis [1]. Nevertheless, the limited supply of hfVM, together with
the variability observed in the outcome of different clinical trials,
along with the appearance of graft-induced dyskinesias (GIDs),
lead to the current need of developing strategies to reproducibly
generate large numbers of neural cells in a safe manner, and under
standardized and controlled conditions (recently reviewed in
[1,2,3,4,5,6,7]. Stem cells promise to be such source of cells.
Importantly, maturation of human neurons and of DA neurons
(DAn) from their precursors is a lengthy process, both in vitro and
in vivo, in experimental animals and humans, requiring at least 5–6
months to take place [8,9,10,11,12]. Therefore, experiments to
document the possible in vivo therapeutic efficacy of stem cells and
their derivatives, along with safety, need to be carefully addressed
in experimental animals on a long-term basis [13,14,15].
At present, the experimental confirmation that transplants of
human Neural Stem Cells (hNSC) of VM origin can lead to long-
term (6–12 months) striatal reinnervation, substantial DA re-
placement and behavioral recovery with a high safety profile, is
still missing [1,2,16].
Our group has recently generated and characterized an
immortalized model cell line of VM hNSC called hVM1, a reliable
source of human A9-subtype DAn, both in vitro and in vivo [17,18].
This non-transformed cell line generates a substantial percentage
of DAn after in vitro differentiation (about 12% of total cells), which
show typical properties of Substantia Nigra pars compacta (A9-
subtype) DAn (reviewed in ref. [18]; see also refs. [8,19].
Behavioral efficacy of transplants of these VM hNSCs has been
consistently reported in the unilateral complete 6-OH-DA rat PD
model. Thus, the transplants result in amelioration of not only
drug (amphetamine, apomorphine)-induced rotational asymmetry
but also spontaneous behavior (e.g., dexterity in the staircase or
paw reaching test) [19,20]. These VM hNSCs loose their
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neurogenic capacity with passaging [20], as reported by other
groups for both rodent and human VM DAn precursors
[21,22,23,24,25,26,27]. We solved this drawback by augmenting
cellular Bcl-XL levels [8,19,20]; reviewed in [18].
The present work aims at the identification of a homogeneous,
clonal source of VM hNSCs and resultant human DAn with
optimal properties for drug screening, developmental studies and,
most of all, cell therapy research. The study was motivated by the
fact that functional maturation of human DAn in vivo requires long
survival times, as explained above, and, when studying the
histology and anatomy of transplants of hVM1 cells, graft
maturation was found to be uneven [19]. In addition, major
differences have been observed between transplants of these
midbrain hNSCs and previous transplantation studies using
forebrain hNSCs. Whereas forebrain hNSCs smoothly integrate
and migrate into the brain parenchyma from the implantation site
(both neurospheres and immortalized cells, refs. [12,28,29], both
hfVM and VM hNSCs show more limited migration, generating
compact transplants [10,19,20,30,31,32]. In the case of hVM1
cells, we have observed a rather immature morphology of the DAn
at 2 months post-grafting, and also areas of the transplants that
were evidently not maturing even at four months post trans-
plantation (see for instance neuronal morphologies in Fig. 9 in ref.
[20] and Fig. 3 in ref. [19]. In addition to the lengthy
differentiation process of human DAn, we hypothesized that
difficulties to achieve full maturation could arise if some of the sub-
clones composing the hVM1 cell line had different maturation
rates, or continued in proliferation, even if that would occur at
a slow rate. To clarify this and to provide homogenous material for
future studies, we have characterized in detail 9 out of 70
previously isolated sub-clones of the hVM1 polyclonal line [17],
previously chosen on the basis of their TH+ neuron generation
rate. Thus, we have identified the best clone candidates for in vivo
PD cell replacement preclinical research based on the number of
v-myc copies in the genome, v-myc down-regulation after in vitro
differentiation, cell cycle exit 2 months after grafting, generation of
TH+ cells both in vitro and in vivo together with the expression of
a mature neuronal marker (human neuron specific enolase,
hNSE). The selected clones show marked cessation of cell division
in comparison with the polyclonal cell line and induce partial
amelioration of behavioral asymmetry even at the short time point
studied here (2 months). We expect that these clonal and
homogeneous VM hNSCs will allow carrying out long-term
transplantation studies to unambiguously determine the safety and
efficacy of VM hNSCs for cell replacement in experimental PD.
Materials and Methods
Ethics Statement
Principles of both laboratory animal care and use of stem cells
were approved by the relevant Research Ethics Comitees, these
being the following: Autonomous University Comitee for Ethical
Research (ref. CEI 23–564), Comision de Seguimiento y Control
de la Donacion y Utilizacion de Celulas y Tejidos Humanos (ref.
123-101-1), Comite Etico de Investigacion Clinica Regional de la
Comunidad de Madrid (ref. OPTISTEM-DA).
All animal work has been designed following the 3Rs principles.
Details of animal work and welfare are described under the
Animal Experimentation section below.
Ethics statements about the human fetal origin of the cells used
in the present study can be found in the original reports describing
hVM1 and hNS1 cell lines [17,33].
Cell Culture Procedures
VM hNSCs (polyclonal line hVM1) overexpressing and non-
overexpressing Bcl-XL and 9 different hVM1 clones pre-isolated in
terms of their TH generation in vitro were routinely cultured on
10 mg/ml poly-L-lysine -pretreated plastic-ware as previously
described [17,20]. Cells were grown at 37uC, in a 95% humidity,
5%CO2 and 5% O2 atmosphere (low oxygen conditions). For
inmunocytochemistry assays, the cells were grown in 50 mg/ml
poly-L-lysine treated sterile round glass cover-slips (0.1 mm
thickness, 13 mm diameter). Differentiation experiments were
performed as described elsewhere [20]. As a control in some
in vitro experiments we used forebrain-derived, immortalized
clonal hNSCs (cell line hNS1, formerly HNSC.100), cultured
and differentiated as described [33].
Genomic DNA Isolation and Southern Blot
Genomic DNA was isolated by incubating cell pellets in lysis
buffer (2% Tris-HCl 1M pH 8, 2% NaCl 5M, 5% SDS 10%, 2%
EDTA 0.5M) containing proteinase K (20 mg/ml) overnight at
55uC. After that, samples were mixed with 300 ml of saturated
NaCl solution and incubated 10 min at 4uC, followed by
centrifugation at maximum speed 20 min. The supernatant was
mixed with 800 ml of iso-propanol and incubated on ice 15 min.
Samples were centrifuged again at maximum speed 20 min and
the pellet rinsed with 70% ethanol, dried and dissolved in water.
For Southern Blotting 10 mg of DNA were digested with EcoRI
(4 h, 37uC). After electrophoresis, DNA was transferred to a nylon
membrane (Hybond N; Amersham) and hybridized with a 1.3 Kb
SacI-BamHI [a-32P] dCTP labeled probe [33].
Protein Extraction and Western Blot (WB) Assays
Total protein was extracted from cultures under proliferation
and also after 10 days of differentiation. Blots were incubated
overnight at 4uC with the following primary antibodies: v-myc
(rabbit-polyclonal, Upstate Biotechnology, 1:400), b-actin (mouse-
monoclonal, Sigma, 1:10000). Immunoreactivity was detected
using the ECL Western blot detection system (Amersham
Biosciences) and the blots were quantified by scanning densitom-
etry using ImageJ (NCBI/NIH) software.
Immunocytochemistry (ICC)
Cultures were fixed under proliferation and after 10 days
differentiation conditions with 4% buffered paraformaldehyde.
Samples were incubated overnight at 4uC in PBS containing 1%
goat serum, 0.25% Triton X-100 with the following primary
antibodies: Ki-67 (Thermo Scientific, 1:200), Nestin (BD Trans-
duction Laboratories, 1:600), b-III-tubulin (Sigma, 1:2000) or TH
(Chemicon, 1:1000). Cultures were rinsed and incubated for 1 h
with fluorescent secondary antibodies: Cy3-conjugated goat anti-
mouse for nestin and b-III-tubulin (1:200, Jackson Inmunore-
search) and Cy5-conjugated donkey anti-rabbit for Ki-67 and TH
(1:200, Jackson Inmunoresearch) and Hoechst 33258 (1:400,
Molecular Probes) to label nuclei. Samples were coverslipped with
Mowiol. Microscopic examination and photography of the
samples were performed by epifluorescence microscopy, and
analyzed with ImageJ (NCBI/NIH) software.
Animal Experimentation: Lesion, Drug-induced Rotation
and Transplantation Procedures
Experiments were carried out according to the guidelines of the
European Community (Directive 86/609/ECC) and in accor-
dance with the Society for Neuroscience recommendations.
Animals used in this study were 3-month-old female Sprague-
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Dawley rats (Harlan), weighing 200–250 g at the beginning of the
experiment.
We chose groups of reduced number of rats (3–5) to apply the
Reduction concept of the 3 Rs principle [34] in view of the large
number of clones to study. Although this low number of animals is
insufficient to generate behavioral data with statistical power, the
most important part of the in vivo studies is the histological analysis,
and for this purpose a number of 3–5 rats suffices.
Animals were housed in a temperature- and humidity-
controlled room, under 12 hours light/dark cycles, with ad libitum
access to food and water. Rats were anesthetized with a ketamine-
xylacine cocktail for all lesion and transplantation surgeries. Rats
received a 6-hydroxydopamine (6-OH-DA) injection (9 mg/3 ml
dissolved in 0.9% saline containing 0.2 mg/ml ascorbic acid;
Sigma) in the right median forebrain bundle at the following
stereotaxic coordinates (tooth bar set at 23.3 mm): antero-
posterior,23.7 mm; medio-lateral,21.6 mm (both from bregma);
dorso-ventral, 28.8 mm from dura. The injection rate was 1 ml/
min, and the syringe was kept in place for an additional 5 min
before being slowly retracted. Four weeks after the lesion, the rats
were tested for rotational behavior in automated rotometer bowls
(Panlab) following an intraperitoneal injection of D-amphetamine
Figure 1. In vivo maturation of VM hNSC transplants. VM hNSCs (hVM1-Bcl-XL) were transplanted into the 6-OH-DA lesioned rat striatum for
a survival time of 2 months. A–C) Tyrosine hydroxylase immunohistochemistry developed with DAB, showing areas in the graft populated with
morphologically immature TH+ neurons (B) and others with mature neurons (C), or devoid of them. D, E) Numerous cells in the grafts were still
engaged in the cell cycle (Ki-67+, panel E) at this survival time. Scale bar in A, E: 500 mm; in B, C: 20 mm.
doi:10.1371/journal.pone.0052714.g001
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sulfate (5 mg/kg, Sigma). Rotation scores were collected every
2 min for 90 min in a computer-assisted rotometer system
(Panlab). Only rats exhibiting 5 or more ipsilateral rotations/
min after D-amphetamine injection were selected for further
transplantation studies. Balanced groups of 3–5 hemiparkinsonian
rats were transplanted with the 9 different clonal hVM1 cell lines
and hVM1 polyclonal cell lines (over-expressing or non-over-
expressing Bcl-XL; 17, 20) in proliferative state. Cells were
trypsinized and resuspended in Ca2+ and Mg2+ containing Hanks’
balanced salt solution (Invitrogen) at a density of 105 cells/ml.
Three ml of cell suspensions (a total of 36105 cells) were injected
into the denervated striatum at the following coordinates (in mm):
antero-posterior, +1; medio-lateral, 23; dorso-ventral, 24.5 (from
dura), with the tooth bar set at 22.3. The animals were
immunosuppressed with daily intraperitoneal cyclosporine A
injection (15 mg/kg; Novartis), starting 2 days before trans-
plantation and throughout the experiment. Seven weeks after
transplantation, the animals were anesthetized with an overdose of
chloral hydrate and intracardially perfused with freshly prepared,
buffered 4% paraformaldehyde (in 0.1M phosphate buffer,
pH 7.4).
Immunohistochemistry (IHC)
Brains were removed after animal perfusion, post-fixed for 12 h
in the same fixative at 4uC, and dehydrated in 30% sucrose
solution at 4uC until sunk. Ten series of 30 mm-thick coronal
sections were collected using a freezing microtome. Serial sections
were used for immunohistochemistry with polyclonal antibodies
against TH (1:400; Pel-freeze) and monoclonal antibodies against
human nuclei (HuNu) (1:100; Chemicon), Ki-67 (1:200, Thermo
Scientific), human neuron-specific enolase (hNSE) (1:1000;
Chemicon). Secondary abtibodies used were biotinylated goat
anti-rabbit (1:200, Vector), biotinylated rabbit anti-sheep (1:200,
Vector), donkey anti-mouse CY5 (1:200, Jackson Inmunoresearch)
Table 1. Global account of the results obtained for the different criteria used.
Polyclonal Clone 1 Clone 2 Clone 3 Clone 13 Clone 15 Clone 16 Clone 28 Clone 30 Clone 32
v-myc copies 4 4 2 3 2 1 2 2 1 2
v-myc downregulation + 2 2 + ++ 2 ++ 2 + +
Ki-67 downregulation ++ + + 2 2 2 2 2 + ++
Nestin downregulation + 2 + ++ + 2 2 2 2 +
Differentiation to ß-III-tub+ cells + + ++ + ++ + 2 2 + ++
Differentiation to TH+ cells + + ++ - ++ + 2 2 + ++
Reduction of Ki-67 in vivo 1 1 1.2 1 2.3 3 1.8 1.5 3 3
hNSE in vivo + nd nd nd nd nd nd nd + +
TH in vivo ++ + + + + + + 2 + +
Rotational compensation + ++ + + + + + + ++ +
Polyclonal = hVM1-Bcl-XL cells. Scoring is presented from low values (2), to one or two (+) signs, being (++) the best result for each parameter. For the in vivo reduction
of Ki- 67 staining, grafts were scored for 1 to 3, being 3 the best score indicating cell cycle exit.
doi:10.1371/journal.pone.0052714.t001
Figure 2. v-myc integrations and downregulation upon differentiation. A) Southern blot showing the number of integrated copies of v-myc
vector in each clone and cellular lines used as controls. Human fibroblasts (Fib), negative control; clonal human forebrain neural stem cells (hNS1),
known to have only one insertion [35]; polyclonal hVM1-BclXL cell line (HB) expected to show multiple integrations since it is composed of a library of
clones. B) Examples of Western blots showing v-myc protein detection. Samples of total protein were extracted under proliferation (Div) and after 10
days of differentiation (d10) conditions for each clone and control cell lines. Note that the clonal hNS1 cells downregulate vector expression whereas
the level of v-myc protein is still high in the HB cells after 10d of differentiation. C) v-myc protein signal in the blots was quantified using Image J
software. The degree of downregulation (10 d/Div) is represented. The extent of down-regulation of v-myc protein obtained for hVM1-Bcl-XL cells
(HB) was 8.3% and was taken as the minimum acceptable down-regulation that a clone should have. Thus, clones with a downregulation over 8.3%
were considered. The value obtained for the downregulation of the clonal forebrain hNS1 cell line, 34.7%, would be the ideal or maximal
downregulation.
doi:10.1371/journal.pone.0052714.g002
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and goat anti-rabbit CY3 (1:200, Jackson Inmunoresearch),
depending on the primary antibody. The sections incubated with
biotinylated secondary antibodies were then incubated with
a complex of avidin-biotin-peroxidase (ABC kit, Vector Labora-
tories) and developed with 1,3-diaminobenzidine (DAB, Sigma).
Finally, the sections were mounted onto gelatinized glass slides
(Menzel-Glaser), dried overnight and coverslipped with Mowiol
for the fluorescent IHC or 1,3-diethyl-8-phenylxanthine (DPX) for
the DAB IHC.
Imaging and Data Analyses
Analysis and photography of fluorescent or DAB stained
samples were carried out in an inverted Zeiss Axiovert 135
(Oberkochen, Germany) or Leica DM IRB microscope equipped
with a digital camera Leica DC100 (Nussloch, Germany). In some
of the immunofluorescence experiments, digitized images were
captured using Leica IM500 or LSM710 software. Image analyses
were performed using NIH Image J software.
Quantification of HuNu+ and Ki-67+ Cells in the Grafts
In order to assess the extent of cell cycle exit in vivo, we
quantified the co-localization of HuNu (Human Nuclei) and Ki-67
protein (cellular marker for proliferation) using NIH Image J
software. Briefly, the whole extent (medio-lateral and dorso-
ventral) of the grafted striatum was analyzed by confocal
microscopy in sections spaced 240 mm (antero-posterior).
Statistics
Student t-tests were ran out to compare data between groups using
Statistika software. A significance level of p,0.001 and p,0.05
was chosen for Student t-test one tail.
Results and Discussion
As pointed out in the Introduction, analysis of polyclonal hVM1
or hVM1- Bcl-XL cell transplants at both 2 and 4 months post-
grafting revealed an immature morphology of TH+ neurons,
together with areas of the transplants devoid of TH+ neurons,
a finding that was confirmed in the present study (see Figure 1A–
C). We processed the transplanted brains (2 months post-grafting)
for HuNu and Ki-67 antigens, finding that there were areas in the
transplants in which the cells were actively engaged in cell division
(Ki-67+) (see Figure 1 D, E). Furthermore, in the worst cases, the
grafts did appear as large, rounded masses of tissue resembling to
what could be defined as overgrowths. Cell karyotype was however
normal (46XY, no structural abnormalities) in the cells, even at
later passages than those used here for transplantation (pass 30,
Ramos-Moreno, unpublished).
Because of these reasons and in order to identify optimal VM
NSCs for future research, we decided to screen a library of clones
that were isolated at the time of generating the parental and
polyclonal cell line hVM1 [17]. Thus, out of a total of 70 clones,
we have chosen 9 clones on the basis of a good rate of TH+
generation to be compared on a number of criteria to the
polyclonal line. Since the hVM1 line overexpressing Bcl-XL shows
a high rate of DAn generation (up to 15–20% of the total cells, see
refs. [8,20], we have considered this line as a reference cell line.
Thus, the hVM1- Bcl-XL cells become the ‘‘gold-standard’’ for the
screening process.
V-myc Copy Numbers and Down-regulation of v-myc
Expression
A poor in vivo down regulation of v-myc expression in the cells
(the v-myc coding retroviral vector gets silenced when the cells are
not exposed to mitogens, see refs. [17,33,35,36] could be one of
the reasons explaining retarded differentiation and/or persistent
cell division of the polyclonal hVM1 and hVM1-Bcl-XL cells. If
multiple copies of the vector co-exist in the same cells, the
likelihood of having too high expression level of v-myc increases,
either because of accumulation of the residual mRNA from
multiple copies of the vector, or because the probability of having
one or more copies not well down-regulated increases.
The number of v-myc retroviral integrations in the genome were
thus studied in the hVM1 sub-clones. Ideally, the most suitable
clone should contain a single v-myc integration at a chromatin
region favoring proper down-regulation of expression upon
differentiation (as previously reported for the clonal hNS1 cells,
refs. [33,35]. Such a clone would be preferred in comparison to
clones bearing more than one v-myc copy. We have used human
fibroblasts as a negative control; the polyclonal hVM1- Bcl-XL cell
line as a cell line likely having multiple v-myc integrations, and the
clonal human neural stem cell line (hNS1) known to have only one
v-myc insertion [33]. In the case of the polyclonal hVM1- Bcl-XL
cells, as expected, the southern blot indicates multiple copies of v-
myc (Figure 2A). Regarding clones, nearly all of them have more
than one insertion, but for clone numbers 15 and 30 (Figure 2A
and Table 1). Some of the clones such as number 13, 28 and 32
seem to be sister clones.
Since the extent of silencing of different v-myc integrated copies
cannot be predicted, we determined the actual content in v-myc
protein before and after differentiation. Total protein samples
from the polyclonal hVM1-Bcl-XL, the monoclonal hNS1 line and
the hVM1 sub-clones were extracted from proliferating cells and
10 days following differentiation, and assayed for v-myc protein
content (Figure 2B). The extent of v-myc down-regulation obtained
for each clone was compared to that shown by hVM1-Bcl-XL and
hNS1 cells. The down-regulation in the polyclonal cell line is
considered as the minimum acceptable (8.3%), and that in hNS1
cells as the ideal one (refs. [33,35]; Figure 2C). Therefore, clones
down-regulating in the accepted interval were # 3, 13, 16, 30, and
32 (Figure 2C and Table 1). As noted before, the number of
insertions not always correlates with the downregulation of the
protein.
Ki-67 Expression Under Differentiation Conditions
Control cell lines and clones were stained for Ki-67 (a marker of
cells engaged in the cell cycle) under proliferation and 10 days
after differentiation conditions in order to know their proliferative
state. Differentiation of both control and Bcl-XL hVM1 cell lines
Figure 3. Analysis of Ki-67 and Nestin expression downregulation, and appearance of neuronal markers following differentiation.
Ki-67 (A) and Nestin (D) immunofluorescence of the control hVM1-Bcl-XL cells (HB) and representative clones under division (Div) and following
differentiation (d10). In both cases, examples are shown of a clone not showing proper downregulation (#3, 28), and of clones showing good cell
cycle exit and disappearance of the NSC marker Nestin (#2, 32). B and E) Quantitative raw data are shown for control HB cells and all clones. C and F)
Percentage of reduction in the number of positive cells for each marker. G) Immunofluorescence for b-III-tubulin and TH of the control hVM1-Bcl-XL
cells (HB) and representative clones after differentiation (d10). Note the difference in neurogenic and DAn generation capacity for the different clones
(H). Clones # 32, 2 and 13 generate more TH+ cells than hVM1-Bcl-XL cells. Clones # 1, 15 and 30 are close to this level. Nuclei were counterstained
with Hoechst 33258 (blue). Scale bar: 20 mm, valid for all panels.
doi:10.1371/journal.pone.0052714.g003
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implies a reduction in the number of Ki-67+ cells of around 20%
by day 7, being this number further reduced (80%) one week later
(Figure S2 in ref. 20). Similar results were obtained for hNS1 cells
[37]. In the present experiments hVM1- Bcl-XL cells showed that
50% of the total cells down-regulated Ki-67 after differentiation
(d10), as predicted (Figure 3C). Therefore, we have considered
a reduction of about 50% of the cells expressing Ki-67 following
10 days of differentiation as an acceptable threshold. Since this is
a short-term experiment (10 days) we expect down-regulation to
further increase during longer differentiation times, according to
ref. 8. As shown in Figure 3 B, C it is only clone #32 the one
showing a near to 50% reduction, being clones # 1, 2, and 30
other examples of clones showing substantial Ki-67 downregula-
tion (Figure 3C and Table 1).
Nestin Expression Downregulation with Differentiation
The percentage of Nestin positive cells should parallel the data
obtained for Ki-67. According to ref. [8], differentiated hVM1
cells cultures show a marked decrease in Nestin expression during
a one-month differentiation (the same is true for hNS1 cells, ref.
[37]). We have analyzed by ICC the expression of nestin in the
selected clones under proliferation conditions and compared these
data to the expression observed after 10 days of differentiation
(Figure 3D–F, percentage of the reduction in Nestin+ cells). We
have again considered as an acceptable threshold the reduction
obtained for hVM1- Bcl-XL. Thus, clones showing a difference
equal or larger to this threshold are clone numbers 2, 3, 13 and 32
(Figure 3F and Table1).
Differentiation and TH+ Neuron Generation
A next step in the screening procedure was to analyze the
neurogenic capacity of the clones, aiming to identify those
producing an optimal number of DAn, in comparison with the
polyclonal hVM1-Bcl-XL line. To this end all cultures were
differentiated in vitro for 10 days, and stained for a general
neuronal marker (b-III-tubulin), and TH (Figure 3G). Some of the
clones (# 2, 13, 32) were clearly superior to the parental line for
the generation of neurons and DAn (Figure 3H). In addition,
clones # 1, 15 and 30 were close to these levels (Table 1).
In Vivo Studies: Cell Cycle Exit, Differentiation and
Behavioral Amelioration
The most challenging criterion to validate the use of any clone is
its in vivo performance. In particular, even at the short survival
time used in the present study, whether the cells stop dividing and
differentiate into the required cell type, DAn in the present case.
To assess this we evaluated the transplants of the clones in
hemiparkinsonian rats at 2 months survival time, in comparison to
the polyclonal hVM1- Bcl-XL cells. Brain sections of each clone
and the polyclonal cell line were stained for the following markers:
a) double staining with Ki-67 and human nuclei (HuNu) to asses
the proliferation of cells in the transplant; b) hNSE to study
whether cells start maturing in the graft and c) Tyrosine
Hydroxylase (TH), to identify DAn in the transplant.
Anatomy of the different grafts showed, in general, a rather
compact mass of cells located in the striatum around the injection
Figure 4. Cessation of cell division in vivo. A–H) Epifluorescence images of HuNu and Ki-67 immunofluorescences in sections of transplanted
animals, two months post-grafting. A–D) Low magnification images comparing the transplants of polyclonal hVM1-Bcl-XL cells (A, B) and
a representative clone (# 30; C, D). HuNu allows for the identification of all human cells in the rat section and Ki-67 labels cells engaged in the cell
cycle. Note the difference in graft volume between the polyclonal cells and the clone, and that the transplant of hVM1-Bcl-XL cells looks heavily
stained for Ki-67. Scale bar in D, 1 mm, valid for A-D. CC, corpus callosum; LV, lateral ventricle. E–H) Higher magnification view of two representative
clones, showing poor (clone # 28; E, F) and good (clone # 32; G, H) downregulation of Ki-67. Scale bar: 40 mm, valid for E-H. I–J) Details of neurons
differentiated in the transplants of clone 32, immunostained for hNSE (I) or TH (J). Scale bar in J: 20 mm, valid for I, J.
doi:10.1371/journal.pone.0052714.g004
Figure 5. Assessment of drug-induced rotation. A) Amphetamine-induced net ipsilateral rotations before (PRE) and 2 months after
transplantation (POST). Note the trend for a partial recovery observed in the majority of animal groups. Since the present work required examination
of many clones, the number of animals per group was kept to a minimum (3–5) and thus non-significant trends are observed. B) Clone 30 transplants
were twice as effective than the polyclonal hVM1-Bcl-XL cel grafts in inducing rotation compensation.
doi:10.1371/journal.pone.0052714.g005
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site (Figure 4). This is probably due to the short post-grafting time
and limited differentiation. Please note that the polyclonal hVM1-
Bcl-XL cells generate a less integrated graft, heavily stained for Ki-
67 (Figure 4A–D, see also Figure 1). Clones were semi-
quantitatively scored for the reduction of proliferating cells, as
indicated in Table 1. Examples of clones showing a majority of the
cells as Ki-67+ (score 1) and others with an evident reduction of
Ki-67+ cells in comparison to HuNu+ cells (score 3) are shown in
Figure 4 E–H. Even when the clones were studied at a short post-
grafting time, in some of them (Table 1) a positive staining for
a mature neuronal marker such as hNSE and also TH+ neurons
were easily detected (Figure 4 I, H).
Amphetamine induced rotation tests were additionally carried out
in all groups of animals at 7 weeks post-lesion. Following
amphetamine administration, all the grafted groups showed net
ipsilateral rotation for the duration of the experiment to a varying
extent (Figure 5A). Grafts of hVM1-Bcl-XL cells reduced rotation
as previously described [19,20] and many of the clones also
showed the same trend. Note that one of the best clones, even in
the absence of increased Bcl-XL levels, did reduce rotation by
27%, close to what is expected for a functional graft. Furthermore,
this clone #30 is clearly superior to its parental cell line (control
hVM1 cells, refs. [19,20]).
Summing up, and according to the majority of in vitro and in vivo
criteria analyzed so far, clones # 30 and 32 are the ones showing
optimal features (Table 1). Therefore, we focused on these two
clones and quantified under the confocal microscope the degree of
cell cycle exit at 2 months post grafting, in comparison to the two
polyclonal hVM1 cell lines, either control or the Bcl-XL over-
expressing one. The control naı¨ve cell line was included in this
quantification since it is the perfect matching control for the
clones. However, we were also interested in knowing if Bcl-XL
could influence the rate of exit from the cell cycle. Of note, in an
in vitro recent study [8] we have concluded that Bcl-XL does not
affect the maturation rate of DAn generated from hVM1 NSCs. In
another in vivo study and based on RT-Q PCR data [20], it
seemed that maturation was more complete in Bcl-XL cells at 2
months post grafting when compared to the naı¨ve control hVM1
cells. In the present study, using quantitative histolgy, at the
sampling frequency used, a total number of 332.407, 258.466,
30.238, and 13.061 HuNu+ cells were identified (and analyzed for
Ki-67 co-expression) in Bcl-XL overexpressing and non over-
expressing hVM1 cell grafts and in clones # 30 and 32 cell grafts,
respectively. Considering that in all animal groups the same
number of cells were transplanted (36105), the one order of
magnitude in difference in the total cells found in the brains may
be the result of continued cell division of the polyclonal lines. A
simple survival effect of Bcl-XL does not account for the large
difference found in total cell numbers. In accordance with the
previous in vitro studies [8], Bcl-XL does not affect the cell cycle
exit in vivo (Figure 6, comparison between the two polyclonal lines).
In the case of the polyclonal cell lines, a 25–35% of the HuNu+
cells were engaged in cell cycle (Ki-67+). The clones analyzed here
showed a better rate of cell cycle exit, around 10–15% (co-
localization of Ki-67 and HuNu, 2 months post-grafting; hVM-
BclXL = 27.7865.04%, hVM1 = 35.7964.83%; clone
#30 = 10.2861.79%; clone #32 = 14.1762.88%) (Figure 6B).
Concluding Remarks and Future Directions
Previous work and present results regarding v-myc immortalized
cells show a down regulation of v-myc levels upon differentiation
both in vitro and in vivo, along with cell integration into the host
tissue following transplantation. Downregulation of v-myc is
essential for the cells to differentiate normally, thus allowing
neuron generation and maturation, and, in the context of
regenerative medicine, to explore the potential of neuron re-
placement in neurodegeneration models, such as those for PD.
Even when the use of immortalized cells (and therefore the
selected clones # 30 and 32 identified here) will be limited to
in vitro and pre-clinical in vivo research, the availability of cell lines
with optimal properties will enable researchers to understand
a major unresolved issue: whether human NSCs of VM origin are
capable of replacing DAn in the denervated striatum in the long-
term and can exert functional effects, namely, behavioral
amelioration. If that would be the case, it is guaranteed that
similar cells to the ones studied so far will be developed for clinical
applications. For that use, the cells should be re-derived and
characterized under clinically acceptable conditions, and by that
time, the use of more sophisticated genetic engineering tools is
envisaged to control integration and expression of v-myc, or to
remove the transgene before transplantation [18].
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